Hyperprolactinemia due to macroprolactin: A commonly unrecognized phenomenon causing misdiagnosis and mismanagement

Endocrinologist

Volumn 18, Issue 5, 2008, Pages 249-254

  McKenna, T Joseph ^a,b   Smith, Thomas ^a  

^a ST VINCENT S UNIVERSITY HOSPITAL   (Ireland)

^b NONE   (Ireland)

Author keywords

Hyperprolactinemia; Macroprolactin; Misdiagnosis

Indexed keywords

PROLACTIN;

AUTOIMMUNITY; DIAGNOSTIC ERROR; HUMAN; HYPERPROLACTINEMIA; NONHUMAN; PROLACTIN BLOOD LEVEL; PROLACTIN RELEASE; REVIEW; SCREENING;

EID: 67649836773     PISSN: 10512144     EISSN: None     Source Type: Journal    
DOI: 10.1097/TEN.0b013e3181880f39     Document Type: Review

References (40)

1. Suliman AM, Smith TP, Gibney J, et al. Frequent misdiagnosis and mismanagement of hyperprolactinemic patients before the introduction of macroprolactin screening: application of a new strict laboratory definition of macroprolactinemia. Clin Chem. 2003;49:1504-1509.
2. Smith TP, Suliman AM, Fahie-Wilson MN, et al. Gross variability in the detection of prolactin in sera containing big big prolactin (macroprolactin) by commercial immunoassays. J Clin Endocrinol Metab. 2002;87:5410-5415.
3. Elin RJ. College of American Pathologists special ligands participants summary report. 2001:7.
4. Klee G. College of American Pathologists special ligands participant summary report. 2007:11.
5. Gibney J, Smith TP, McKenna TJ. The impact on clinical practice of routine screening for macroprolactin. J Clin Endocrinol Metab. 2005;90:3927-3932.
6. Hattori N, Ikekubo K, Ishihara T, et al. A normal ovulatory woman with hyperprolactinemia: presence of anti-prolactin autoantibody and the regulation of prolactin secretion. Acta Endocrinol (Copenh). 1992;126:497-500.
7. Leite V, Cosby H, Sobrinho LG, et al. Characterization of big, big prolactin in patients with hyperprolactinaemia. Clin Endocrinol (Oxf). 1992;37:365-372.
8. Cavaco B, Leite V, Santos MA, et al. Some forms of big big prolactin behave as a complex of monomeric prolactin with an immunoglobulin G in patients with macroprolactinemia or prolactinoma. J Clin Endocrinol Metab. 1995;80:2342-2346.
9. Hattori N, Ikekubo K, Nakaya Y, et al. Immunoglobulin G subclasses and prolactin (PRL) isoforms in macroprolactinemia due to anti-PRL autoantibodies. J Clin Endocrinol Metab. 2005;90:3036-3044.
10. Casanueva FF, Molitch ME, Schlechte JA, et al. Guidelines of the pituitary society for the diagnosis and management of prolactinomas. Clin Endocrinol. 2006;65:265-273.
11. Schlechte JA. The macroprolactin problem. J Clin Endocrinol Metab. 2002;87:5408-5409.
12. Fahie-Wilson M. In hyperprolactinemia, testing for macroprolactin is essential. Clin Chem. 2003;49:1434-1436.
13. Rogol AD, Rosen SW. Prolactin of apparent large molecular size: the major immunoactive prolactin component in plasma of a patient with a pituitary tumor. J Clin Endocrinol Metab. 1974;38:714-717.
14. Freeman ME, Kanyicska B, Lerant A, et al. Prolactin: structure, function, and regulation of secretion. Physiol Rev. 2000;80:1523-1631.
15. Ichihara K, Miyai K. Detection of asymptomatic prolactinoma by a mass screening program. Rinsho Byori. 1990;38:667-674.
16. Bjoro T, Morkrid L, Wergeland R, et al. Frequency of hyperprolactinaemia due to large molecular weight prolactin (150-170 kD PRL). Scand J Clin Lab Invest. 1995;55:139-147.
17. Fraser IS, Lun ZG, Zhou JP, et al. Detailed assessment of big big prolactin in women with hyperprolactinemia and normal ovarian function. J Clin Endocrinol Metab. 1989;69:585-592.
18. Bjoro T, Johansen E, Frey HH, et al. Different responses in little and bigbig prolactin to metoclopramide in subjects with hyperprolactinemia due to 150-170 kD (bigbig) prolactin. Acta Endocrinol (Copenh). 1993;128:308-312.
19. Larrea F, Escorza A, Valero A, et al. Heterogeneity of serum prolactin throughout the menstrual cycle and pregnancy in hyperprolactinemic women with normal ovarian function. J Clin Endocrinol Metab. 1989;68:982-987.
20. Alhquist JAO, Fahie-Wilson M. The origin and distribution of macroprolactin. Paper presented at: 19th Meeting of the British Endocrine Societies; 2000; Birmingham, UK.
21. Fahie-Wilson MN, Soule SG. Macroprolactinaemia: contribution to hyperprolactinaemia in a district general hospital and evaluation of a screening test based on precipitation with polyethylene glycol. Ann Clin Biochem. 1997;34:252-258.
22. Vieira JG, Tachibana TT, Obara LH, et al. Extensive experience and validation of polyethylene glycol precipitation as a screening method for macroprolactinemia. Clin Chem. 1998;44:1758-1759.
23. Olukoga AO, Kane JW. Macroprolactinaemia: validation and application of the polyethylene glycol precipitation test and clinical characterization of the condition. Clin Endocrinol (Oxf). 1999;51:119-126.
24. Leslie H, Courtney CH, Bell PM, et al. Laboratory and clinical experience in 55 patients with macroprolactinemia identified by a simple polyethylene glycol precipitation method. J Clin Endocrinol Metab. 2001;86:2743-2746.
25. Hauache OM, Rocha AJ, Maia AC, et al. Screening for macroprolactinaemia and pituitary imaging studies. Clin Endocrinol (Oxf). 2002;57:327-331.
26. Strachan MW, Teoh WL, Don-Wauchope AC, et al. Clinical and radiological features of patients with macroprolactinaemia. Clin Endocrinol (Oxf). 2003;59:339-346.
27. Gibney J, Smith TP, McKenna TJ. Clinical relevance of macroprolactin. Clin Endocrinol (Oxf). 2005;62:633-643.
28. Vallette-Kasic S, Morange-Ramos I, Selim A, et al. Macroprolactinemia revisited: a study on 106 patients. J Clin Endocrinol Metab. 2002;87:581-588.
29. Hattori N, Ikekubo K, Ishihara T, et al. Correlation of the antibody titers with serum prolactin levels and their clinical course in patients with anti-prolactin autoantibody. Eur J Endocrinol. 1994;130:438-445.
30. Molitch ME. Medical management of prolactin-secreting pituitary adenomas. Pituitary. 2002;5:55-65.
31. Molitch ME, Russell EJ. The pituitary "incidentaloma." Ann Intern Med. 1990;112:925-931.
32. Olukoga AO, Dornan TL, Kane JW. Three cases of macroprolactinaemia. J R Soc Med. 1999;92:342-344.
33. Cattaneo F, Kappeler D, Muller B. Macroprolactinaemia, the major unknown in the differential diagnosis of hyperprolactinaemia. Swiss Med Wkly. 2001;131:122-126.
34. Kavanagh L, McKenna TJ, Fahie-Wilson M, et al. Specificity and clinical utility of methods for the detection of macroprolactin. Clin Chem. 2006;52:1366-1372.
35. Healy M-L, Smith TP, McKenna TJ. Diagnosis, misdiagnosis and management of hyperprolactinemia. Expert Rev Endocrinol Metab. 2006;1:123-131.
36. Sturgeon CM, Ellis AR, Al-Sadie R, et al. Annual Review. Edinburgh, UK: UK National External Quality Assessment Scheme; 2006.
37. Gaffney TA, O'Kane DJ. Macroprolactin-big-big molecules create big problems in diagnosis of hyperprolactinemia. Mayo Med Labs Commun. 2007;32:1-4.
38. Fahie-Wilson M, McKenna TJ, Ahlquist JA, et al. Macroprolactin and the Pituitary Society guidelines for the management of prolactinomas. Clin Endocrinol. 2007;67:638-639.
39. Leanos-Miranda A, Chavez-Rueda KA, Blanco-Favela F. Biologic activity and plasma clearance of prolactin-IgG complex in patients with systemic lupus erythematosus. Arthritis Rheum. 2001;44:866-875.
40. Hattori N, Nakayama Y, Kitagawa K, et al. Development of anti-PRL (prolactin) autoantibodies by homologous PRL in rats: a model for macroprolactinemia. Endocrinology. 2007;148:2465-2470.